Fig. 8
From: Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma
MNPC suppresses tumor growth of U87MG/EGFRvIII cells in the brain and elongates mouse life span. a Nu/Nu nude mice were treated with increasing doses (3, 10 mg/kg) of MNPC by i.p. every two days for a total of 10 doses (n = 6 mice per group). The survival curves of brain tumor-bearing mice were calculated. b Weight of intracranial model mice treated with MNPC (3, 10 mg/kg) or control vehicle. c Quantitative analysis of intracranial tumor volume in the mice treated with MNPC (3, 10 mg/kg) or control vehicle. d IHC of 4-HNE, Ki67, TUNEL and H&E in tumor nodules from MNPC (3, 10 mg/kg) or control vehicle-treated mice. e Chronic MNPC treatment displayed no detectable toxicity. Histological analysis of hematoxylin–eosin-stained tissue sections of representative mice in MNPC or vehicle-treated group. Scale bar: 100 μm. f Western blot analysis of intracranial tumor lysates from the animals treated with MNPC (3, 10 mg/kg) or control vehicle. Data are means ± SEM (*p < 0.05, one-way ANOVA)